Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis

ObjectiveTo clarify the screening potential of the Amsler grid and preferential hyperacuity perimetry (PHP) in detecting or ruling out wet age-related macular degeneration (AMD).Evidence acquisitionMedline, Scopus and Web of Science (by citation of reference) were searched. Checking of reference lists of review articles and of included articles complemented electronic searches. Papers were selected, assessed, and extracted in duplicate.Evidence synthesisSystematic review and meta-analysis. Twelve included studies enrolled 903 patients and allowed constructing 27 two-by-two tables. Twelve tables reported on the Amsler grid and its modifications, twelve tables reported on the PHP, one table assessed the MCPT and two tables assessed the M-charts. All but two studies had a case–control design. The pooled sensitivity of studies assessing the Amsler grid was 0.78 (95% confidence intervals; 0.64–0.87), and the pooled specificity was 0.97 (95% confidence intervals; 0.91–0.99). The corresponding positive and negative likelihood ratios were 23.1 (95% confidence intervals; 8.4–64.0) and 0.23 (95% confidence intervals; 0.14–0.39), respectively. The pooled sensitivity of studies assessing the PHP was 0.85 (95% confidence intervals; 0.80–0.89), and specificity was 0.87 (95% confidence intervals; 0.82–0.91). The corresponding positive and negative likelihood ratios were 6.7 (95% confidence intervals; 4.6–9.8) and 0.17 (95% confidence intervals; 0.13–0.23). No pooling was possible for MCPT and M-charts.ConclusionResults from small preliminary studies show promising test performance characteristics both for the Amsler grid and PHP to rule out wet AMD in the screening setting. To what extent these findings can be transferred to a real clinic practice still needs to be established.

[1]  J. Hillenkamp,et al.  Diagnostik von Metamorphopsien bei Netzhauterkrankungen unterschiedlicher Genese , 2006, Der Ophthalmologe.

[2]  P. Jüni,et al.  Consequences of different diagnostic "gold standards" in test accuracy research: Carpal Tunnel Syndrome as an example. , 2005, International journal of epidemiology.

[3]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[4]  Kang Zhang,et al.  Shape discrimination test on handheld devices for patient self-test , 2010, IHI.

[5]  Albert O Edwards,et al.  Shape discrimination in age-related macular degeneration. , 2002, Investigative ophthalmology & visual science.

[6]  Amitha Domalpally,et al.  Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. , 2014, Ophthalmology.

[7]  Patrick M Bossuyt,et al.  We should not pool diagnostic likelihood ratios in systematic reviews , 2008, Statistics in medicine.

[8]  J. R. Ferencz,et al.  TOWARD EARLIER DETECTION OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION: Multicenter Evaluation of a Preferential Hyperacuity Perimeter Designed as a Home Device , 2010, Retina.

[9]  N. Bressler,et al.  Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study. , 2005, Ophthalmology.

[10]  R. Mathew,et al.  Environmental Amsler test as a monitoring tool for retreatment with ranibizumab for neovascular age-related macular degeneration , 2012, Eye.

[11]  A. Grzybowski,et al.  M-charts as a tool for quantifying metamorphopsia in age-related macular degeneration treated with the bevacizumab injections , 2013, BMC Ophthalmology.

[12]  G. E. Lang,et al.  [Comparison of Preferential Hyperacuity Perimeter (PHP) test and Amsler grid test in the diagnosis of different stages of age-related macular degeneration]. , 2006, Klinische Monatsblatter fur Augenheilkunde.

[13]  Glenn J Jaffe,et al.  Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. , 2013, Ophthalmology.

[14]  Gary Rubin,et al.  The Amsler chart: absence of evidence is not evidence of absence , 2007, British Journal of Ophthalmology.

[15]  FUNCTIONAL AND MORPHOLOGIC BENEFITS IN EARLY DETECTION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION USING THE PREFERENTIAL HYPERACUITY PERIMETER , 2011, Retina.

[16]  Wolfgang Fink,et al.  Distinguishing wet from dry age-related macular degeneration using three-dimensional computer-automated threshold Amsler grid testing , 2011, British Journal of Ophthalmology.

[17]  Lucas M. Bachmann,et al.  An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. , 2008, Journal of clinical epidemiology.

[18]  T. Ciulla,et al.  Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. , 2006, Archives of ophthalmology.

[19]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[20]  Rafael Malach,et al.  Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. , 2003, Ophthalmology.

[21]  Gerald Liew,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.

[22]  M. Amsler,et al.  L'Examen qualitatif de la fonction maculaire , 1947 .

[23]  M. Elman,et al.  Earliest symptoms caused by neovascular membranes in the macula. , 1986, Archives of ophthalmology.

[24]  R. Guymer,et al.  Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. , 2012, American journal of ophthalmology.

[25]  C. Matsumoto,et al.  Correlations between M-CHARTS and PHP findings and subjective perception of metamorphopsia in patients with macular diseases. , 2011, Investigative ophthalmology & visual science.

[26]  R. Malach,et al.  RESULTS OF A MULTICENTER CLINICAL TRIAL TO EVALUATE THE PREFERENTIAL HYPERACUITY PERIMETER FOR DETECTION OF AGE-RELATED MACULAR DEGENERATION , 2005, Retina.

[27]  Peter K. Kaiser,et al.  FEASIBILITY OF A NOVEL REMOTE DAILY MONITORING SYSTEM FOR AGE-RELATED MACULAR DEGENERATION USING MOBILE HANDHELD DEVICES: Results of a Pilot Study , 2013, Retina.

[28]  P. Bossuyt,et al.  Empirical evidence of design-related bias in studies of diagnostic tests. , 1999, JAMA.

[29]  Song Zhang,et al.  Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. , 2013, Investigative ophthalmology & visual science.

[30]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[31]  M. Ávila,et al.  Comparison of the original Amsler grid with the preferential hyperacuity perimeter for detecting choroidal neovascularization in age-related macular degeneration. , 2007, Arquivos brasileiros de oftalmologia.

[32]  R. Chou,et al.  Screening Older Adults for Impaired Visual Acuity: A Review of the Evidence for the U.S. Preventive Services Task Force , 2009, Annals of Internal Medicine.